GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Research & Development

IXICO (LSE:IXI) Research & Development : £0.93 Mil (TTM As of Sep. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IXICO Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. IXICO's Research & Development for the six months ended in Sep. 2023 was £0.46 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was £0.93 Mil.


IXICO Research & Development Historical Data

The historical data trend for IXICO's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Research & Development Chart

IXICO Annual Data
Trend Sep13 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 1.31 1.24 1.22 0.93

IXICO Semi-Annual Data
Sep13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.63 0.59 0.46 0.46

IXICO Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IXICO  (LSE:IXI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


IXICO Research & Development Related Terms

Thank you for viewing the detailed overview of IXICO's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


IXICO (LSE:IXI) Business Description

Traded in Other Exchanges
Address
15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines